ContributorsPublishersAdvertisers

Pembrolizumab Shows Improvements in Disease-Free Survival as Adjuvant Treatment for Non-Small Cell Lung Cancer

pharmacytimes.com
 2022-01-18

Cover picture for the articleThe findings from the phase 3 KEYNOTE-091 trial mark the first positive study for pembrolizumab in adjuvant stage IB-IIIA non-small cell lung cancer. New study results with adjuvant pembrolizumab show statistically significant improvements in disease-free survival (DFS) among patients with stage IB-IIIA non-small cell lung cancer (NSCLC) regardless of programmed death-ligand...

www.pharmacytimes.com

Comments / 0

Comments / 0